Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00680758 · ClinicalTrials.gov registry record · Phase 1
Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer
A Phase 1 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00680758 is a Phase 1 study that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 18 participants.
The verdict
NCT00680758, a Phase 1 study, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving more than one drug (combination chemotherapy) together with everolimus may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of cisplatin, paclitaxel, and everolimus when given together for the treatment of patients with metastatic breast cancer.
Interventions
- DRUG cisplatin
- DRUG paclitaxel
- DRUG everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00680758
The ClinicalTrials.gov registry entry for NCT00680758 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00680758 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00680758 about?
NCT00680758 is a clinical study titled "Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Givi...
What is the current status of trial NCT00680758?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2008-05. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00680758?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), everolimus (DRUG).
Who is sponsoring clinical trial NCT00680758?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.